JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) — Today Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of the innovative alpha radiation cancer therapy Alpha DaRT™, and MIM Software Inc. (“MIM Software”), a leading global provider of medical imaging software, announced a partnership between the two companies to provide treatment planning software for clinical sites using Alpha DaRT therapy.
Under the terms of the agreement, the parties will collaborate to leverage MIM’s software suite, including MIM Symphony and MIMcloud®, to develop new features and support the Alpha DaRT for multiple potential indications, integration into all clinical trials involving the Alpha is involved. DaRT, and bundling the MIM software with the Alpha DaRT for future commercial sale in territories where the Alpha DaRT and MIM software are both approved.
The MIM Symphony treatment planning software guides clinicians through a simple step-by-step process to accurately place Alpha DaRT sources and create a personalized treatment plan for the patient. MIM’s proprietary image manipulation capabilities, including MIM ReSlicer, and process and data management with MIM Workflows and MIMcloud, enable MIM Symphony to flexibly support treatment planning for multiple disease sites. Versatile guidance capabilities, including the ability to create custom 3D-printed access devices, help position Alpha DaRT for challenging targets.
“We are excited to take this next step in our long-standing relationship with MIM,” said Uzi Sofer, CEO of Alpha Tau. “As we’ve been working with MIM for the past few years, we’ve seen the ability of this software to make treatment planning easier and more powerful for the clinicians using the Alpha DaRT, and we’re very excited to integrate our technologies and deliver the best therapeutic provide cancer care. patients. We continue to see increasing response rates in our clinical trials, culminating in the release of our most recent data from our US pilot study treating skin cancer, where we observed a 100% complete response at 12 and 24 weeks post-treatment. We believe that our enhanced treatment planning capabilities, including those developed with our colleagues at MIM, have played a significant role in that achievement.” Alpha Tau Chief Operating Officer, Amnon Gat, added: “Our experience with the MIM team has been fantastic and has instilled confidence that together we can continue to develop new treatment planning methods and workflows for our pipeline indications such as brain cancer, pancreas and liver.”
“Our partnership with Alpha Tau is an excellent opportunity for MIM to influence radiotherapy and patient outcomes,” said Andy Nelson, CEO of MIM Software. “We are very pleased with the response rates and excited to be involved in providing an improved patient experience with Alpha DaRT.” Jon Piper, Chief Scientific Officer of MIM Software, added: “It has been great to work with Alpha Tau to improve outcomes for patients with limited capabilities. We are hopeful that the planning, quality assurance and standardization that MIM provides will enable clinicians to realize the potential of this transformational modality.”
About Alpha DaRT
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha irradiation of solid tumors through intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse as they emit high-energy alpha particles with the aim of destroying the tumor. Because the alpha-emitting atoms only diffuse a short distance, Alpha DaRT mainly aims to affect the tumor and spare the healthy tissue around it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company focused on research, development and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari of Tel Aviv University.
About MIM Software Inc.
MIM Software is committed to improving patient care by providing customer-centric and innovative medical imaging and planning solutions in the fields of radiotherapy, brachytherapy, radiology, nuclear medicine, urology, neuroimaging and cardiac imaging. The company’s products are used in more than 5,000 centers worldwide.
MIM Software Inc. is a privately held company headquartered in Cleveland, OH, with international offices in Beijing, Chengdu and Brussels.
For more information, visit mimsoftware.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “are”, “will”, “plan”, “may”, “continue” , and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characteristics of future events or conditions, including underlying assumptions, are forward-looking. All forward-looking statements are based on Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there are reasonable grounds for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize his expectations and his beliefs turn out to be incorrect. Actual results could differ materially from those described or implied by such forward-looking statements as a result of several important factors, including, but not limited to: (i) Alpha Tau’s ability to obtain regulatory approval for its Alpha DaRT business technology or future products or product candidates; (ii) Alpha Tau’s limited business history; (iii) significant losses to date from Alpha Tau; (iv) Alpha Tau’s need for additional financing and the ability to raise capital as needed; (v) Alpha Tau’s limited experience in discovering and developing medical devices; (vi) Alpha Tau’s reliance on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical trials to predict final trial results; (viii) failure of the early clinical studies or preclinical studies of Alpha Tau to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) unwanted side effects caused by Alpha Tau’s Alpha DaRT technology or future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations that apply to it; (xiii) ability to comply with Nasdaq’s listing standards; (xiv) costs associated with being a limited liability company; (xv) changes in applicable law or regulation; (xix) effects of the COVID-19 pandemic; and the other important factors discussed under the heading “Risk Factors” in Alpha Tau’s annual report filed on Form 20-F with the SEC on March 28, 2022, and other filings that Alpha Tau makes with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated in the forward-looking statements contained in this press release. Such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon to represent the views of Alpha Tau as of a date after the date of this press release.
Contact person for investor relations
For Alpha Tau: IR@alphatau.com
For MIM: firstname.lastname@example.org